July 7, 2014

The theme for this year’s Cardinal Health RBC 2014 is “Leading Change.” For community pharmacists, that means playing a more active role in patient care. And Cardinal Health has a suite of services to help community pharmacists take the next step in making a difference in their patients’ lives — the Cardinal Health Adherence Suite.

June 25, 2014

Cardinal Health on Wednesday outlined a number of enhanced tools to make it easier for retail pharmacies to help their patients better manage their cardiovascular health and prevent heart disease.

June 19, 2014

Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.

June 12, 2014

Former chairman and CEO for Time Warner Cable, Glenn Britt, died Wednesday at his home after fighting cancer, according to reports. He was 65 years old.

June 11, 2014

Cardinal Health on Wednesday announced that CFO Jeff Henderson will retire following the completion of fiscal year 2015, after a decade in the role.

June 4, 2014

Cardinal Health on Wednesday launched a new solution to make it easier and more time-efficient for retail pharmacies to help patients better understand and adhere to their medications.

June 3, 2014

Actavis last week announced that it has reached an agreement with Cephalon to settle all outstanding patent litigation associated with Actavis' generic version of Nuvigil (armodafinil tablets).

May 28, 2014

Actavis on Tuesday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration seeking approval to market saxagliptin hydrochloride tablets, 2.5 mg and 5 mg.

May 27, 2014

A series of new clinical studies released Tuesday found that Cardinal Health Specialty Solutions’ Clinical Pathways program reduces the cost of cancer treatment, improves clinical care and shows promise for guiding treatment of other high-cost, complex diseases beyond cancer.

May 15, 2014

Actavis has reached an agreement with Janssen Pharmaceuticals to continue supplying the authorized generic version of Janssen's Concerta (methylphenidate hydrochloride extended-release tablets), the company announced.

May 14, 2014

Actavis on Tuesday announced that it has received final approval from the Food and Drug Administration on its abbreviated new drug application for a generic version of Mallinckrodt's Exalgo (hydromorphone hydrochloride extended-release tablets 8 mg, 12 mg and 16 mg).

May 14, 2014

Actavis on Wednesday announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Labs, which is anticipated at mid-year.

May 12, 2014

Perrigo on Monday announced that it received approval from the Food and Drug Administration for azelastine hydrochloride nasal spray (0.15%), a generic version of Astepro. The drug is indicated for people ages 12 years and older and is used to treat nasal symptoms brought on by seasonal allergies or environmental irritants.

May 12, 2014

Actavis on Monday announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%.

May 8, 2014

Actavis announced that it has launched a generic version of Boehringer Ingelheim's Catapres-TTS (clonidine transdermal system, USP, 0.1-mg/day, 0.2-mg/day, and 0.3-mg/day for one week).

May 1, 2014

Cardinal Health on Thursday reported fiscal year 2014 third-quarter revenue of $21.4 billion and non-GAAP diluted earnings per share from continuing operations of $1.01.

April 29, 2014

Endo International on Tuesday announced that it will acquire Somar, a privately-owned specialty pharmaceuticals company based in Mexico City, Mexico.

April 28, 2014

Cardinal Health on Monday announced that its board of directors elected David J. Anderson as an independent director. Anderson most recently served as SVP and CFO of Honeywell International. He also will serve on the board's audit committee.

April 24, 2014

Endo International announced that its affiliates have acquired rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use from Zogenix.

April 18, 2014

Actavis on Friday announced that it has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration.

April 18, 2014

Actavis and Forest Laboratories on Thursday announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Forest.

April 16, 2014

Among severely obese people, vitamin D may make the difference between an active and a more sedentary lifestyle, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism on Tuesday.

April 15, 2014

Actavis on Tuesday announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).

April 7, 2014

Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.